BPMC Blueprint Medicines
- 90.730
- -1.530-1.66%
- 90.730
- 0.0000.00%
Blueprint Medicines News
Blueprint Medicines: Buy Rating Affirmed on BLU-808 Prospects and Strong Ayvakit Sales Forecast
Blueprint Medicines Analyst Ratings
Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH)
Blueprint Medicines Analyst Ratings
Buy Rating Affirmed for Blueprint Medicines on Strong Ayvakit Clinical Performance and Promising Pipeline
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)
Blueprint Medicines: Sell Rating Justified by Gavreto Divestiture and Strategic Shift
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
Blueprint Medicines Sell Rating: Assessing Ayvakit's Market Potential and Financial Concerns
Blueprint Medicines Analyst Ratings
Sell Rating on Blueprint Medicines Amidst Concerns Over Long-Term Growth and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Blueprint Medicines (BPMC) and Medtronic (MDT)
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
Blueprint Medicines Receives Buy Rating Amid Surpassing Sales and Optimistic Financial Outlook
Blueprint Medicines Analyst Ratings
Blueprint Medicines (BPMC) Receives a Hold From Barclays
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX), Urogen Pharma (URGN) and Blueprint Medicines (BPMC)
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Blueprint Medicines (BPMC)
Blueprint Medicines Analyst Ratings
Analysis
Price Target
No Data
